Cardiol Therapeutics (TSE:CRDL) Receives “Buy” Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Cardiol Therapeutics (TSE:CRDL) in a report published on Monday, BayStreet.CA reports.

Cardiol Therapeutics Trading Down 3.6 %

Shares of TSE:CRDL opened at C$2.40 on Monday. The company has a market capitalization of C$156.26 million, a P/E ratio of -5.58 and a beta of 0.75. Cardiol Therapeutics has a 1 year low of C$0.74 and a 1 year high of C$2.94. The company has a debt-to-equity ratio of 0.52, a current ratio of 5.29 and a quick ratio of 6.84. The business’s 50 day simple moving average is C$2.30 and its 200 day simple moving average is C$1.62.

About Cardiol Therapeutics

Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx for patients hospitalized with COVID-19, as well as for the treatment of recurrent pericarditis and acute myocarditis.